abstract |
The cancer gene therapeutic drug of the present invention includes a carrier cell for infecting an oncolytic virus and causing the same virus to act on tumor cells, and A549 cells and 293 cells in which strong anti-tumor effects are recognized as such carrier cells. , SW626 cells, HT-3 cells are used. The present invention can obtain a strong antitumor effect as compared with a conventional carrier cell by using these cells in which high antitumor effect is recognized in both in vitro and in vivo as carrier cells. |